Position in CYTK
as of Jun 30, 2026
· filed Aug 21, 2026
Position Value
$5,816,347
+$2,567,314 QoQ
Shares Held
68,275
+38.5% QoQ
Ownership
0.049%
of shares outstanding
% of Portfolio
1.23%
of 13F equity value
Holder Rank
#153
of 477 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARVEY CAPITAL MANAGEMENT INC holds $42,449,117 across 7 Biotechnology names. CYTK ranks #4 (13.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
146,113 | $11,436,264 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
138,835 | $10,340,430 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
26,913 | $6,485,225 | |
| 4 | CYTK |
Cytokinetics Inc
This page
|
68,275 | $5,816,347 | |
| 5 | ARGX |
Argenx SE
|
4,346 | $4,032,088 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,975 | $3,102,111 | |
| 7 | ABVX |
Abivax S.A.
|
9,280 | $1,236,652 |
All Filings in CYTK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,816,347 | 68,275 | Shares | Sole | 2026-08-21 | |
| 2026-03-31 | $3,249,033 | 49,295 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $2,974,307 | 46,810 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,172,296 | 21,330 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $724,567 | 21,930 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $907,490 | 22,580 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $1,039,819 | 22,105 | Shares | Sole | 2025-01-29 | |
| No filing history on record for this holder in this stock. | ||||||